Clinical Trial: JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07081022) titled 'JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma' on July 15.

Brief Summary: To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma

Study Start Date: Aug. 19

Study Type: INTERVENTIONAL

Condition: B-cell Non-Hodgkin's Lymphoma

Intervention: DRUG: JS203 in combination with gemcitabine and oxaliplatin

Gemcitabine and oxaliplatin 8 cycles (Q3W) and JS203 (21 days/cycle) Cycle 1 QW,Cycle 2 and therafter Q3W until progression or unacceptable toxicity.

DRUG: JS203 in combination with ifosfamide, carboplatin and etoposide

Ifosfamide, carboplatin and et...